Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.
Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas where parasite resistance to a...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4410941?pdf=render |
| _version_ | 1811205571523641344 |
|---|---|
| author | Elisa Sicuri Silke Fernandes Eusebio Macete Raquel González Ghyslain Mombo-Ngoma Achille Massougbodgi Salim Abdulla August Kuwawenaruwa Abraham Katana Meghna Desai Michel Cot Michael Ramharter Peter Kremsner Laurence Slustker John Aponte Kara Hanson Clara Menéndez |
| author_facet | Elisa Sicuri Silke Fernandes Eusebio Macete Raquel González Ghyslain Mombo-Ngoma Achille Massougbodgi Salim Abdulla August Kuwawenaruwa Abraham Katana Meghna Desai Michel Cot Michael Ramharter Peter Kremsner Laurence Slustker John Aponte Kara Hanson Clara Menéndez |
| author_sort | Elisa Sicuri |
| collection | DOAJ |
| description | Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas where parasite resistance to antifolate drugs is high. The cost-effectiveness of IPTp with alternative drugs is needed to inform policy.The cost-effectiveness of 2-dose IPTp-mefloquine (MQ) was compared with IPTp-SP in HIV-negative women (Benin, Gabon, Mozambique and Tanzania). In HIV-positive women the cost-effectiveness of 3-dose IPTp-MQ added to CTXp was compared with CTXp alone (Kenya, Mozambique and Tanzania). The outcomes used were maternal clinical malaria, anaemia at delivery and non-obstetric hospital admissions. The poor tolerability to MQ was included as the value of women's loss of working days. Incremental cost-effectiveness ratios (ICERs) were calculated and threshold analysis undertaken.For HIV-negative women, the ICER for IPTp-MQ versus IPTp-SP was 136.30 US$ (2012 US$) (95%CI 131.41; 141.18) per disability-adjusted life-year (DALY) averted, or 237.78 US$ (95%CI 230.99; 244.57), depending on whether estimates from Gabon were included or not. For HIV-positive women, the ICER per DALY averted for IPTp-MQ added to CTXp, versus CTXp alone was 6.96 US$ (95%CI 4.22; 9.70). In HIV-negative women, moderate shifts of variables such as malaria incidence, drug cost, and IPTp efficacy increased the ICERs above the cost-effectiveness threshold. In HIV-positive women the intervention remained cost-effective for a substantial (up to 21 times) increase in cost per tablet.Addition of IPTp with an effective antimalarial to CTXp was very cost-effective in HIV-positive women. IPTp with an efficacious antimalarial was more cost-effective than IPTp-SP in HIV-negative women. However, the poor tolerability of MQ does not favour its use as IPTp. Regardless of HIV status, prevention of malaria in pregnancy with a highly efficacious, well tolerated antimalarial would be cost-effective despite its high price.ClinicalTrials.gov NCT 00811421; Pan African Trials Registry PACTR2010020001429343 and PACTR2010020001813440. |
| first_indexed | 2024-04-12T03:34:41Z |
| format | Article |
| id | doaj.art-8f09c4f2c29947218c2357c13083a205 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T03:34:41Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8f09c4f2c29947218c2357c13083a2052022-12-22T03:49:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012507210.1371/journal.pone.0125072Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.Elisa SicuriSilke FernandesEusebio MaceteRaquel GonzálezGhyslain Mombo-NgomaAchille MassougbodgiSalim AbdullaAugust KuwawenaruwaAbraham KatanaMeghna DesaiMichel CotMichael RamharterPeter KremsnerLaurence SlustkerJohn AponteKara HansonClara MenéndezIntermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas where parasite resistance to antifolate drugs is high. The cost-effectiveness of IPTp with alternative drugs is needed to inform policy.The cost-effectiveness of 2-dose IPTp-mefloquine (MQ) was compared with IPTp-SP in HIV-negative women (Benin, Gabon, Mozambique and Tanzania). In HIV-positive women the cost-effectiveness of 3-dose IPTp-MQ added to CTXp was compared with CTXp alone (Kenya, Mozambique and Tanzania). The outcomes used were maternal clinical malaria, anaemia at delivery and non-obstetric hospital admissions. The poor tolerability to MQ was included as the value of women's loss of working days. Incremental cost-effectiveness ratios (ICERs) were calculated and threshold analysis undertaken.For HIV-negative women, the ICER for IPTp-MQ versus IPTp-SP was 136.30 US$ (2012 US$) (95%CI 131.41; 141.18) per disability-adjusted life-year (DALY) averted, or 237.78 US$ (95%CI 230.99; 244.57), depending on whether estimates from Gabon were included or not. For HIV-positive women, the ICER per DALY averted for IPTp-MQ added to CTXp, versus CTXp alone was 6.96 US$ (95%CI 4.22; 9.70). In HIV-negative women, moderate shifts of variables such as malaria incidence, drug cost, and IPTp efficacy increased the ICERs above the cost-effectiveness threshold. In HIV-positive women the intervention remained cost-effective for a substantial (up to 21 times) increase in cost per tablet.Addition of IPTp with an effective antimalarial to CTXp was very cost-effective in HIV-positive women. IPTp with an efficacious antimalarial was more cost-effective than IPTp-SP in HIV-negative women. However, the poor tolerability of MQ does not favour its use as IPTp. Regardless of HIV status, prevention of malaria in pregnancy with a highly efficacious, well tolerated antimalarial would be cost-effective despite its high price.ClinicalTrials.gov NCT 00811421; Pan African Trials Registry PACTR2010020001429343 and PACTR2010020001813440.http://europepmc.org/articles/PMC4410941?pdf=render |
| spellingShingle | Elisa Sicuri Silke Fernandes Eusebio Macete Raquel González Ghyslain Mombo-Ngoma Achille Massougbodgi Salim Abdulla August Kuwawenaruwa Abraham Katana Meghna Desai Michel Cot Michael Ramharter Peter Kremsner Laurence Slustker John Aponte Kara Hanson Clara Menéndez Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. PLoS ONE |
| title | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. |
| title_full | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. |
| title_fullStr | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. |
| title_full_unstemmed | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. |
| title_short | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. |
| title_sort | economic evaluation of an alternative drug to sulfadoxine pyrimethamine as intermittent preventive treatment of malaria in pregnancy |
| url | http://europepmc.org/articles/PMC4410941?pdf=render |
| work_keys_str_mv | AT elisasicuri economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT silkefernandes economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT eusebiomacete economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT raquelgonzalez economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT ghyslainmombongoma economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT achillemassougbodgi economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT salimabdulla economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT augustkuwawenaruwa economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT abrahamkatana economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT meghnadesai economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT michelcot economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT michaelramharter economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT peterkremsner economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT laurenceslustker economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT johnaponte economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT karahanson economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy AT claramenendez economicevaluationofanalternativedrugtosulfadoxinepyrimethamineasintermittentpreventivetreatmentofmalariainpregnancy |